Humanitas University

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Retrieved on: 
Friday, March 15, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, MSD, OS, Chemoradiotherapy, CRT, Obstetrics, Congress, Gynaecology, CPS, Survival, Disease, Progression-free survival, Data monitoring committee, Cervical cancer, Patient, Neoplasm, Merck & Co., Overalls, Humanitas University, Bevacizumab, MRK, Cancer, ESMO, PFS, FIGO, PD-L1, Food, Pharmaceutical industry

At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.

Key Points: 
  • At a pre-specified interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with concurrent CRT showed a statistically significant and clinically meaningful improvement in OS versus concurrent CRT alone.
  • The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.
  • Results will be presented at an upcoming medical meeting and shared with regulatory authorities worldwide.
  • As previously reported , KEYNOTE-A18 met its other primary endpoint of progression-free survival (PFS) in 2023.

Cell Reports Medicine Publication Demonstrates How Gelesis’ Oral Therapeutic Hydrogel Promotes Weight Loss and Metabolic Health by Targeting the Gut-Liver Axis in Pre-Clinical Studies

Retrieved on: 
Tuesday, October 17, 2023
Research, FDA, Diabetes, Fitness & Nutrition, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Paper, Sugar, Multimedia, Gel, DSM-IV codes, OSH, Doctor of Philosophy, Obesity, Hydrogel, Prevalence, Weight loss, Gelesis, Diet-induced obesity model, Metabolic syndrome, Humanitas University, Inulin, NASH, Psyllium, Liver disease, Fatty liver disease, Growth, NAFLD, Dietary supplement, Akkermansia

The reported studies examined both the efficacy and mechanism of action of Gelesis’ oral superabsorbent hydrogels (OSH) in preclinical models of diet-induced obesity, metabolic syndrome, and NASH.

Key Points: 
  • The reported studies examined both the efficacy and mechanism of action of Gelesis’ oral superabsorbent hydrogels (OSH) in preclinical models of diet-induced obesity, metabolic syndrome, and NASH.
  • The Gelesis OSH consistently resulted in weight loss, improved insulin sensitivity, and prevented the progression of NAFLD.
  • The study also demonstrated that the beneficial metabolic effects were independent of the weight loss effect.
  • “Our work shows the potential of oral superabsorbent hydrogels to be an effective and non-invasive therapeutic tool in the long-term treatment of obesity and metabolic disorders.”

FUJIFILM Europe launches new virtual scale solution to address challenges faced by endoscopists in polyp measurement

Retrieved on: 
Friday, April 21, 2023
ESGE, EYE, Fujifilm, CAD, Cancer, Innovation system, Research, Large intestine, Associate, Colon, Colorectal cancer, SCALE, Patient, Physician, Hearing, Colonoscopy, Diagnosis, Polyp, Medical imaging, Gastroenterology, Humanitas University

To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.

Key Points: 
  • To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.
  • Integrated into FUJIFILM's ELUXEO Ultra platform, SCALE EYE enables endoscopists to measure polyps more accurately and as a result, support physicians to determine the treatment needed by simply pressing a switch.
  • Despite 90 percent of the endoscopists agreeing on the importance of polyp measurement, the majority use visual estimation, open biopsy forceps, or endoscopic rulers, rather than innovative solutions.
  • [2]
    Prof Cesare Hassan, Associate Professor of Gastroenterology, Humanitas University, Italy said: "SCALE EYE is a disruptive technology by Fujifilm.

FUJIFILM Europe launches new virtual scale solution to address challenges faced by endoscopists in polyp measurement

Retrieved on: 
Friday, April 21, 2023
ESGE, EYE, Fujifilm, CAD, Cancer, Innovation system, Research, Large intestine, Associate, Colon, Colorectal cancer, SCALE, Patient, Physician, Hearing, Colonoscopy, Diagnosis, Polyp, Medical imaging, Gastroenterology, Humanitas University

To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.

Key Points: 
  • To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.
  • Integrated into FUJIFILM's ELUXEO Ultra platform, SCALE EYE enables endoscopists to measure polyps more accurately and as a result, support physicians to determine the treatment needed by simply pressing a switch.
  • Despite 90 percent of the endoscopists agreeing on the importance of polyp measurement, the majority use visual estimation, open biopsy forceps, or endoscopic rulers, rather than innovative solutions.
  • [2]
    Prof Cesare Hassan, Associate Professor of Gastroenterology, Humanitas University, Italy said: "SCALE EYE is a disruptive technology by Fujifilm.

LUMENDI KEY OPINION LEADER, DR. ROBERTA MASELLI, RECEIVES INNOVATION OF THE YEAR AWARD FOR THE BEST NEW DEVICE FROM THE EUROPEAN SOCIETY OF GASTROINTESTINAL ENDOSCOPY (ESGE)

Retrieved on: 
Thursday, April 20, 2023
Society, ESGE, Extrapyramidal system, Gastrointestinal Endoscopy, Endoscopy, Assistant, Congress, Rectum, Balloon, ESD, European Society of Neurogastroenterology and Motility, Humanitas University, Safety, Award, Medical device

MAIDENHEAD, United Kingdom, April 20, 2023 /PRNewswire/ -- UK-based medical device innovator Lumendi Ltd., today announced that the European Society of Gastrointestinal Endoscopy (ESGE) has awarded company consultant and key opinion leader, Dr. Roberta Maselli, Assistant Professor of Gastroenterology at Humanitas University in Milan, Italy, the 'Best New Device" award for the Balloon Endo-Luminal Lumen Occluding (BELLO) Device. The prestigious award was presented to Dr. Maselli earlier today, at the Society's ESGE Days 2023 congress, currently being held in Dublin, Ireland through April 22, 2023, and virtually.

Key Points: 
  • The prestigious award was presented to Dr. Maselli earlier today, at the Society's ESGE Days 2023 congress, currently being held in Dublin, Ireland through April 22, 2023, and virtually.
  • The BELLO is a new, modified device designed to facilitate technically demanding endoscopic submucosal dissection procedures of the lower gastrointestinal tract, especially of rectal lesions.
  • "The BELLO is an important innovation and upon approval, would allow safer, more efficient submucosal dissection procedures in the rectum.
  • With its numerous potential benefits, including improved safety, accuracy, and patient comfort, it has the ability to revolutionize the way early gastrointestinal neoplasia are treated," stated Dr. Maselli.

Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics

Retrieved on: 
Wednesday, November 2, 2022
Oncology, Health, Diabetes, Fitness & Nutrition, General Health, Clinical Trials, Pharmaceutical, Security (finance), Human, Inulin, Nature, Growth, Type 2 diabetes, Failure, Annual report, Humanitas University, Nutritional science, NAFLD, Abdomen, Gel, U.S. Securities and Exchange Commission, Obesity, GLS, Exercise, Diet, 100,000, XXV, Patient, NYSE, Diarrhea, Risk, Industry, COVID-19, Functional constipation, Bacteria, Intellectual property, Flatulence, Psyllium, Use, Non-alcoholic fatty liver disease, Absorption, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Body mass index, Defecation, Gelatin, Incidence, NASH, BMI, Social media, Food, Perception, FDA, Elasticity, Allergy, Pain scale, Cellulose, Multimedia, Social conditioning, New, Environment, Forward-looking statement, Citric acid, Gum arabic, Dietary supplement, Risk management, Hydrogel

Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.

Key Points: 
  • Gelesis Holdings Inc. (NYSE: GLS) (Gelesis or the Company) the maker of Plenity for weight management, today released new data at Obesity Week in San Diego.
  • The group found that A. muciniphila grows in the presence of Gel-B as early as two weeks post-treatment.
  • These data are an important step forward in understanding how oral superabsorbent hydrogels induce beneficial changes to the microbiome.
  • We are looking forward to conducting further studies in this area to understand how these changes will translate to humans, said Elaine Chiquette, Gelesis Chief Scientific Officer.

ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

Retrieved on: 
Friday, June 10, 2022
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Other Health, CR, Brentuximab vedotin, Lymphocytopenia, EDT, Company, HSCT, Diffuse large B-cell lymphoma, Biomedical sciences, Genmab, Control, Anemia, Humanitas University, ORR, LinkedIn, Progression-free survival, CEST, Forward-looking statement, Immunogenic cell death, European Hematology Association, Hypophosphatemia, Jaguar XK, BV, Hope, DOR, ADC, U.S. Securities and Exchange Commission, Camidanlumab tesirine, FDA, Hematopoietic stem cell transplantation, Patient, Therapy, Neutropenia, Cancer, PD-1, Technology, NYSE, Lymphatic system, Hodgkin lymphoma, Twitter, MD, Clinical trial, CD25, Department, PBD, Biologics license application, Thrombocytopenia, PFS, GBS, Enzyme, Hematology, Fine chemical, Pharmaceutical industry, San Francisco Bay Area, Camisole

ADC Therapeutics SA (NYSE: ADCT) announced today results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma.

Key Points: 
  • ADC Therapeutics SA (NYSE: ADCT) announced today results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in relapsed or refractory (r/r) Hodgkin lymphoma.
  • Cami has demonstrated consistently favorable response rates and durability in Hodgkin lymphoma patients who have relapsed, despite using the best available treatments.
  • Cami is being evaluated in a pivotal Phase 2 clinical trial in patients with relapsed or refractory Hodgkin lymphoma and a Phase 1b clinical trial as monotherapy and in combination with pembrolizumab in solid tumors.
  • Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors.

ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress

Retrieved on: 
Thursday, May 12, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Other Health, Department, Lymphoma, DNA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Company, Lymphoid leukemia, Humanitas University, Immunogenic cell death, Hospital, Food, Enzyme, PBD, MD, Distortion, 2021 Essex County Council election, Patient, Biomedical sciences, DNA repair, Camidanlumab tesirine, View, ADC, Hodgkin lymphoma, Therapy, Diffuse large B-cell lymphoma, Hematology, Genmab, Induced cell cycle arrest, Control, Lymphatic system, Adult, BLA, Relapse, FDA, Genetics, B-cell lymphoma, DLBCL, CHL, NYSE, European Hematology Association, Technology, LinkedIn, Twitter, Cancer, CD25, Jaguar XK, Pharmaceutical industry, Vaccine, Fine chemical, Camisole, Safety, San Francisco Bay Area

As we advance Cami toward a potential BLA submission, we look forward to sharing these data with the hematology community at EHA2022.

Key Points: 
  • As we advance Cami toward a potential BLA submission, we look forward to sharing these data with the hematology community at EHA2022.
  • Once bound to a CD25-expressing cell, Cami is internalized into the cell where enzymes release the PBD-based payload, killing the cell.
  • In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
  • ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

Retrieved on: 
Tuesday, March 8, 2022
Nasdaq, Atopic dermatitis, Humanitas University, Primary biliary cholangitis, Twitter, American Academy, AAD, Itch, Company, Oral, Department, Webcast, FDA, Instagram, MTR, Mount Sinai, Q&A, Icahn School of Medicine at Mount Sinai, KARE, GLOBE, News, Patient, American Academy of Dermatology, Chronic kidney disease, Therapy, Biomedical sciences, LinkedIn, Pharmaceutical industry, Dietary supplement, MD, Medicine

STAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KARE Phase 2 clinical trial evaluating Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients will be presented in a late-breaking oral presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting, to be held March 25-29, 2022, in Boston, MA.

Key Points: 
  • ET on March 11, 2022, which will focus on the initiation of Oral KORSUVA (difelikefalin) Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis, respectively.
  • Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus.
  • The Companys novel KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
  • Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.